StreetInsider.com News Articles

Form DEFA14A Transcode Therapeutics,

Tue, 03 Mar 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260303/26101343.html

Form DEFA14A Transcode Therapeutics,

Tue, 03 Mar 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260303/26101343.html

Form 8-K Transcode Therapeutics, For: Mar 02

Tue, 03 Mar 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260303/26101272.html

Form 8-K Transcode Therapeutics, For: Mar 02

Tue, 03 Mar 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260303/26101272.html

TransCode licenses cancer immunotherapy platform in stock deal

Tue, 03 Mar 2026 08:03:22 -0500

TransCode Therapeutics Inc. (NASDAQ: RNAZ) announced it entered into an exclusive, worldwide, royalty-free license agreement with Unleash Immuno Oncolytics Inc. to develop three drug candidates: UIO-524, UIO-525 and UIO-526.

Under the agreement, Unleash will receive 1,136,364 shares of a new series of non-voting convertible preferred stock from TransCode, convertible into an equal number of common stock shares. The preferred stock represents 6.8% of TransCode's common stock on a fully diluted basis assuming conversion of all outstanding preferred stock.

The lead candidate UIO-524 is designed as an oncolytic adenovirus engineered to replicate within malignant cells and cancer-associated stroma. The virus delivers cytokines CD40-L,

TransCode licenses cancer immunotherapy platform in stock deal

Tue, 03 Mar 2026 08:03:22 -0500

The lead candidate UIO-524 is designed as an oncolytic adenovirus engineered to replicate within malignant cells and cancer-associated stroma. The virus delivers cytokines CD40-L,

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the

Tue, 03 Mar 2026 08:01:00 -0500

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.

BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the

Tue, 03 Mar 2026 08:01:00 -0500

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the

Tue, 03 Mar 2026 08:01:00 -0500

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the

Tue, 03 Mar 2026 08:01:00 -0500

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.

Form 8-K Transcode Therapeutics, For: Feb 23

Mon, 23 Feb 2026 08:11:00 -0500

si-local-file:///var/storage/secattach/20260223/26039710.html

Form 8-K Transcode Therapeutics, For: Feb 23

Mon, 23 Feb 2026 08:11:00 -0500

si-local-file:///var/storage/secattach/20260223/26039710.html

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development